ProCE Banner Activity

A New Paradigm: Targeted Therapies for Acute Myeloid Leukemia

Clinical Thought
New drugs and drug combinations, particularly targeted therapies, are changing the treatment paradigm for patients with newly diagnosed and relapsed/refractory AML.

Released: October 15, 2018

Expiration: October 14, 2019

No longer available for credit.

Share

Faculty

Farhad Ravandi

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by educational grants from

Actinium

Astellas Text

Boston Biomedical

Celgene

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Farhad Ravandi, MD, has disclosed that he has received consulting fees from Agios, Amgen, Ariad, Astellas, Jazz, and Orsenix and funds for research support from AbbVie, Amgen, Bristol-Myers Squibb, Seattle Genetics, and Xencor.